Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906197 | 1.00 | GRIN1 (0.39) | GRIN1GRIN2AGRIN2BTP53CYP1A2 | |
| SCHEMBL24828881 | 0.96 | GRIN1 (0.37) | GRIN1GRIN2AGRIN2BTP53CYP1A2 | |
| SCHEMBL9906211 | 0.94 | GRIN1 (0.39) | GRIN1GRIN2AGRIN2BTP53CYP1A2 | |
| SCHEMBL19479169 | 0.92 | GRIN1 (0.37) | GRIN1GRIN2AGRIN2BTP53CYP1A2 | |
| SCHEMBL23476607 | 0.90 | FOLH1 (0.35) | FOLH1CHIT1DPP4 | |
| SCHEMBL13558099 | 0.88 | GRIN1 (0.35) | GRIN1GRIN2AGRIN2BTP53CYP1A2 | |
| SCHEMBL15982269 | 0.87 | GRIN1 (0.35) | GRIN1GRIN2AGRIN2BTP53CYP1A2 | |
| SCHEMBL13558148 | 0.86 | GRIN1 (0.39) | GRIN1GRIN2AGRIN2BTP53CYP1A2 | |
| SCHEMBL19448807 | 0.86 | GRIN1 (0.40) | GRIN1GRIN2AGRIN2BTP53CYP1A2 | |
| SCHEMBL16644695 | 0.84 | CHIT1 (0.37) | FOLH1CHIT1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260077071-A1 | Targeted Delivery of Theranostic Agents | PETER MACCALLUM CANCER INST (AU) | 2026-03-19 | — | — | US | claimed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4594337-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | Rayzebio, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4493578-A1 | TARGETED DELIVERY OF THERANOSTIC AGENTS | Peter MacCallum Cancer Institute (AU) | 2025-01-22 | — | — | EP | claimed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | claimed |
| US-20240342322-A1 | Netrin-1 detection, companion test and therapy based on radiations | CENTRE LEON BERARD (FR) | 2024-10-17 | — | — | US | claimed |
| CN-118593732-A | Myocarditis nuclide molecular probe and preparation method and application thereof | 华中科技大学同济医学院附属同济医院 | 2024-09-06 | — | — | CN | claimed |
| EP-4377341-A1 | NETRIN-1 DETECTION, COMPANION TEST AND THERAPY BASED ON RADIATIONS | Netris Pharma (FR) | 2024-06-05 | — | — | EP | claimed |
| WO-2024073622-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-04-04 | — | — | WO | claimed |
| CN-117813326-A | Method for detection, concomitant testing and treatment of radiation-based guide-1 | 奈特里斯药物公司 | 2024-04-02 | — | — | CN | claimed |
| WO-2023173174-A1 | TARGETED DELIVERY OF THERANOSTIC AGENTS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2023-09-21 | — | — | WO | claimed |
| WO-2023006748-A1 | NETRIN-1 DETECTION, COMPANION TEST AND THERAPY BASED ON RADIATIONS | NETRIS PHARMA (FR) | 2023-02-02 | — | — | WO | claimed |
| CN-114081969-A | Labeled small molecule antibody, and labeling method and application thereof | 成都纽瑞特医疗科技股份有限公司 | 2022-02-25 | — | — | CN | claimed |
| WO-2026101949-A1 | COMPOUNDS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | RAYZEBIO, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260124327-A1 | Compounds Targeting Carbonic Anhydrase IX and Uses Thereof | RAYZEBIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | MDS (CANADA) INC. (CA) | 2009-08-13 | — | — | US | disclosed |
| WO-2007104135-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | MDS (CANADA) INC. (CA) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077071-A1 | Targeted Delivery of Theranostic Agents | CCKAR, NPY1R, NPY2R | GRIN1 1990/4885GRIN2A 2755/4885GRIN2B 2278/4885 |
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | LPXN, FCGRT, POLQ | GRIN1 1051/4885GRIN2A 1680/4885GRIN2B 1860/4885 |
| US-20260124327-A1 | Compounds Targeting Carbonic Anhydrase IX and Uses Thereof | CA9, CA13, CA4 | GRIN1 3833/4885GRIN2A 4240/4885GRIN2B 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.